TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Group Focused Psychosocial Support to Improve the Psychosocial Well-being and Functioning of Adults Affected by Humanitarian Crisis in Nepal
Brief Summary: This is an effectiveness study of group problem management plus, a low-intensity psychological intervention, delivered in five sessions to adults affected by humanitarian crises. The current study will evaluate the effectiveness of Group Problem Management Plus (PM+).


Options:
A: Arm Label: Collaborative Stepped Care; Type: EXPERIMENTAL; Interventions: Other: Collaborative Stepped Care Intervention | Arm Label: Enhanced Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Enhanced Usual Care | Intervention Type: OTHER; Name: Collaborative Stepped Care Intervention; Assigned to Arm(s): Collaborative Stepped Care | Intervention Type: OTHER; Name: Enhanced Usual Care; Assigned to Arm(s): Enhanced Usual Care
B: Arm Label: Group problem management plus; Type: EXPERIMENTAL; Interventions: Behavioral: Group problem management plus | Arm Label: Enhanced treatment as usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced treatment as usual | Intervention Type: BEHAVIORAL; Name: Group problem management plus; Assigned to Arm(s): Group problem management plus | Intervention Type: BEHAVIORAL; Name: Enhanced treatment as usual; Assigned to Arm(s): Enhanced treatment as usual
C: Arm Label: Wait List Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Trauma Focused Cognitive Behavioral Therapy | Intervention Type: BEHAVIORAL; Name: Trauma Focused Cognitive Behavioral Therapy; Assigned to Arm(s): Intervention Group
D: Arm Label: Family-Focused Psychosocial Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Family-Focused, Community-Based, Resilience-Targetting Psychosocial Intervention | Arm Label: Waiting List Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Family-Focused, Community-Based, Resilience-Targetting Psychosocial Intervention; Assigned to Arm(s): Family-Focused Psychosocial Intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Group Focused Psychosocial Support to Improve the Psychosocial Well-being and Functioning of Adults Affected by Humanitarian Crisis in Nepal
Brief Summary: This is an effectiveness study of group problem management plus, a low-intensity psychological intervention, delivered in five sessions to adults affected by humanitarian crises. The current study will evaluate the effectiveness of Group Problem Management Plus (PM+).


Options:
A: Arm Label: Cognitive Behavioral Therapy Intervention for Anxiety; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Therapy Intervention for Anxiety | Arm Label: Enhanced Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy Intervention for Anxiety; Assigned to Arm(s): Cognitive Behavioral Therapy Intervention for Anxiety
B: Arm Label: Care as usual; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Collaborations in Health (COACH); Type: EXPERIMENTAL; Interventions: Behavioral: Collaborations in Health (COACH) | Intervention Type: BEHAVIORAL; Name: Collaborations in Health (COACH); Assigned to Arm(s): Collaborations in Health (COACH)
C: Arm Label: Group problem management plus; Type: EXPERIMENTAL; Interventions: Behavioral: Group problem management plus | Arm Label: Enhanced treatment as usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced treatment as usual | Intervention Type: BEHAVIORAL; Name: Group problem management plus; Assigned to Arm(s): Group problem management plus | Intervention Type: BEHAVIORAL; Name: Enhanced treatment as usual; Assigned to Arm(s): Enhanced treatment as usual
D: Arm Label: Home Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Home based, flexible, stepped care intervention | Arm Label: Wait-list; Type: OTHER; Interventions: Behavioral: Home based, flexible, stepped care intervention after 6 months. Families will be free to choose any health care they desire during the waiting period. | Intervention Type: BEHAVIORAL; Name: Home based, flexible, stepped care intervention; Assigned to Arm(s): Home Care | Intervention Type: BEHAVIORAL; Name: Home based, flexible, stepped care intervention after 6 months. Families will be free to choose any health care they desire during the waiting period.; Assigned to Arm(s): Wait-list

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Adding a Personalised Smoking Cessation Intervention to a Lung Cancer Screening Programme
Brief Summary: Lung cancer rates are higher in Yorkshire than the rest of the UK, and this is due to higher rates of smoking. Deaths from lung cancer can be reduced using regular lung scans (screening) and by helping people stop smoking. As well as detecting cancers, scans can also show evidence of damage to lungs (emphysema) and heart arteries (calcification). This study will test whether people can be encouraged to quit smoking by giving them pictures from their own scans showing possible lung and heart damage, along with information about how stopping smoking reduces their risk of cancer and heart attacks.


Options:
A: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Sugar Pil; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Sugar Pil
B: Arm Label: Varenicline pre-treatmemt; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline, Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Placebo, Varenicline pre-treatmemt | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Intervention | Intervention Type: OTHER; Name: Intervention; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care
D: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Adding a Personalised Smoking Cessation Intervention to a Lung Cancer Screening Programme
Brief Summary: Lung cancer rates are higher in Yorkshire than the rest of the UK, and this is due to higher rates of smoking. Deaths from lung cancer can be reduced using regular lung scans (screening) and by helping people stop smoking. As well as detecting cancers, scans can also show evidence of damage to lungs (emphysema) and heart arteries (calcification). This study will test whether people can be encouraged to quit smoking by giving them pictures from their own scans showing possible lung and heart damage, along with information about how stopping smoking reduces their risk of cancer and heart attacks.


Options:
A: Arm Label: EGO/CE4, 9mg nicotine; Type: OTHER; Interventions: Device: EGO/CE4, 9mg nicotine | Intervention Type: DEVICE; Name: EGO/CE4, 9mg nicotine; Assigned to Arm(s): EGO/CE4, 9mg nicotine
B: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline Tartarate | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Varenicline Tartarate; Assigned to Arm(s): varenicline
C: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Intervention | Intervention Type: OTHER; Name: Intervention; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care
D: Arm Label: 0.8 mg nicotine with 9 mg tar; Type: EXPERIMENTAL; Interventions: Other: very low nicotine content cigarettes | Arm Label: 0.26 mg nicotine with 9 mg tar; Type: EXPERIMENTAL; Interventions: Other: very low nicotine content cigarettes | Arm Label: 0.12 mg nicotine with 9 mg tar; Type: EXPERIMENTAL; Interventions: Other: very low nicotine content cigarettes | Arm Label: 0.07 mg nicotine with 9 mg tar; Type: EXPERIMENTAL; Interventions: Other: very low nicotine content cigarettes | Arm Label: 0.03 mg nicotine with 9 mg tar; Type: EXPERIMENTAL; Interventions: Other: very low nicotine content cigarettes | Arm Label: 0.04 mg nicotine with 13 mg tar; Type: EXPERIMENTAL; Interventions: Other: very low nicotine content cigarettes | Arm Label: Usual brand; Type: OTHER; Interventions: Other: very low nicotine content cigarettes | Intervention Type: OTHER; Name: very low nicotine content cigarettes; Assigned to Arm(s): 0.03 mg nicotine with 9 mg tar, 0.04 mg nicotine with 13 mg tar, 0.07 mg nicotine with 9 mg tar, 0.12 mg nicotine with 9 mg tar, 0.26 mg nicotine with 9 mg tar, 0.8 mg nicotine with 9 mg tar, Usual brand

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Adding a Personalised Smoking Cessation Intervention to a Lung Cancer Screening Programme
Brief Summary: Lung cancer rates are higher in Yorkshire than the rest of the UK, and this is due to higher rates of smoking. Deaths from lung cancer can be reduced using regular lung scans (screening) and by helping people stop smoking. As well as detecting cancers, scans can also show evidence of damage to lungs (emphysema) and heart arteries (calcification). This study will test whether people can be encouraged to quit smoking by giving them pictures from their own scans showing possible lung and heart damage, along with information about how stopping smoking reduces their risk of cancer and heart attacks.


Options:
A: Arm Label: EGO/CE4, 9mg nicotine; Type: OTHER; Interventions: Device: EGO/CE4, 9mg nicotine | Intervention Type: DEVICE; Name: EGO/CE4, 9mg nicotine; Assigned to Arm(s): EGO/CE4, 9mg nicotine
B: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Intervention | Intervention Type: OTHER; Name: Intervention; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care
C: Arm Label: E-Cig Zero Nicotine; Type: SHAM_COMPARATOR; Interventions: Device: E-Cig Zero Nicotine | Arm Label: E-Cig 24mg Nicotine; Type: ACTIVE_COMPARATOR; Interventions: Device: E-Cig 24mg Nicotine | Intervention Type: DEVICE; Name: E-Cig Zero Nicotine; Assigned to Arm(s): E-Cig Zero Nicotine | Intervention Type: DEVICE; Name: E-Cig 24mg Nicotine; Assigned to Arm(s): E-Cig 24mg Nicotine
D: Arm Label: E-cigarettes only; Type: N/A; Interventions: N/A | Arm Label: Traditional cigarettes only; Type: N/A; Interventions: N/A | Arm Label: Mixed group; Type: N/A; Interventions: N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Adding a Personalised Smoking Cessation Intervention to a Lung Cancer Screening Programme
Brief Summary: Lung cancer rates are higher in Yorkshire than the rest of the UK, and this is due to higher rates of smoking. Deaths from lung cancer can be reduced using regular lung scans (screening) and by helping people stop smoking. As well as detecting cancers, scans can also show evidence of damage to lungs (emphysema) and heart arteries (calcification). This study will test whether people can be encouraged to quit smoking by giving them pictures from their own scans showing possible lung and heart damage, along with information about how stopping smoking reduces their risk of cancer and heart attacks.


Options:
A: Arm Label: Ecig 24 mg nicotine; Type: EXPERIMENTAL; Interventions: Device: Ecig 24 mg nicotine | Arm Label: Ecig 0 mg nicotine; Type: SHAM_COMPARATOR; Interventions: Device: Ecig 0 mg nicotine | Arm Label: Nicotine free inhalator; Type: PLACEBO_COMPARATOR; Interventions: Device: Nicotine free inhalator | Intervention Type: DEVICE; Name: Ecig 24 mg nicotine; Assigned to Arm(s): Ecig 24 mg nicotine | Intervention Type: DEVICE; Name: Ecig 0 mg nicotine; Assigned to Arm(s): Ecig 0 mg nicotine | Intervention Type: DEVICE; Name: Nicotine free inhalator; Assigned to Arm(s): Nicotine free inhalator
B: Arm Label: E-Cigarette; Type: EXPERIMENTAL; Interventions: Other: E-Cigarette Vs. Smoking as Usual | Arm Label: Assessment Only; Type: ACTIVE_COMPARATOR; Interventions: Other: E-Cigarette Vs. Smoking as Usual | Intervention Type: OTHER; Name: E-Cigarette Vs. Smoking as Usual; Assigned to Arm(s): Assessment Only, E-Cigarette
C: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Intervention | Intervention Type: OTHER; Name: Intervention; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care
D: Arm Label: E-Cigarette 7.2 mg nicotine; Type: EXPERIMENTAL; Interventions: Device: E-Cigarette 7.2 mg nicotine | Intervention Type: DEVICE; Name: E-Cigarette 7.2 mg nicotine; Assigned to Arm(s): E-Cigarette 7.2 mg nicotine

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Human Controlled Infection Study to Establish a Safe, Reproducible and Practical Human Bordetella Pertussis Colonisation Model for the Identification of Correlates of Protection Against Colonisation (BPCCS)
Brief Summary: This is a prospective controlled human challenge study consisting of two phases; Phase A: Development of a B. pertussis human challenge model; pilot to establish the standard inoculum Phase B: Development of a modified B. pertussis human challenge model


Options:
A: Arm Label: Phase A - SI; Type: EXPERIMENTAL; Interventions: Biological: Bordetella Pertussis B1917, Drug: Azithromycin 500 mg | Arm Label: Phase B Inoculum; Type: EXPERIMENTAL; Interventions: Biological: Bordetella Pertussis B1917, Drug: Azithromycin 500 mg | Arm Label: Phase B Sham; Type: EXPERIMENTAL; Interventions: Drug: Azithromycin 500 mg, Other: Sterile Saline | Intervention Type: BIOLOGICAL; Name: Bordetella Pertussis B1917; Assigned to Arm(s): Phase A - SI, Phase B Inoculum | Intervention Type: DRUG; Name: Azithromycin 500 mg; Assigned to Arm(s): Phase A - SI, Phase B Inoculum, Phase B Sham | Intervention Type: OTHER; Name: Sterile Saline; Assigned to Arm(s): Phase B Sham
B: Arm Label: Group 1: DTaP-IPV-Hep B-PRP-T; Type: EXPERIMENTAL; Interventions: Biological: DTaP-IPV-HB-PRP~T | Arm Label: Group 2: CombAct-HIB™ + OPV; Type: EXPERIMENTAL; Interventions: Biological: CombAct-HIB® | Arm Label: Group 3: DTaP-IPV-Hep B-PRP-T (ENGERIX B™ at birth); Type: ACTIVE_COMPARATOR; Interventions: Biological: Engerix B® Pediatric | Intervention Type: BIOLOGICAL; Name: DTaP-IPV-HB-PRP~T; Assigned to Arm(s): Group 1: DTaP-IPV-Hep B-PRP-T | Intervention Type: BIOLOGICAL; Name: CombAct-HIB®; Assigned to Arm(s): Group 2: CombAct-HIB™ + OPV | Intervention Type: BIOLOGICAL; Name: Engerix B® Pediatric; Assigned to Arm(s): Group 3: DTaP-IPV-Hep B-PRP-T (ENGERIX B™ at birth)
C: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Biological: Boostrix, Biological: Infanrix hexa | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Biological: Boostrix, Biological: Quinvaxem, Biological: OPV | Intervention Type: BIOLOGICAL; Name: Boostrix; Assigned to Arm(s): Group A, Group B | Intervention Type: BIOLOGICAL; Name: Infanrix hexa; Assigned to Arm(s): Group A | Intervention Type: BIOLOGICAL; Name: Quinvaxem; Assigned to Arm(s): Group B | Intervention Type: BIOLOGICAL; Name: OPV; Assigned to Arm(s): Group B
D: Arm Label: Allergy Cases; Type: N/A; Interventions: N/A | Arm Label: Controls; Type: N/A; Interventions: N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluating the Impact of Assessing During Peer Review the CONSORT Checklist Submitted by Authors: a Randomised Controlled Trial
Brief Summary: Randomised trials are considered the gold standard in medical research. The CONSORT (Consolidated Standards of Reporting Trials) Statement aims to improve the quality of reporting of randomised trials. Without transparent reporting, readers cannot judge the reliability and validity of trial findings, and therefore these findings cannot inform clinical practice. Different stakeholders, including biomedical journals, have taken different actions to try to improve author adherence to CONSORT. The most popular action among biomedical journals is to instruct authors to submit a completed RG checklist with page numbers indicating where the CONSORT items are addressed when they submit their manuscript. However, this measure alone has been proven not to be effective. In this study, the investigators intend to evaluate in a real editorial context whether assessing during peer review the consistency between the submitted CONSORT checklist and the information reported in the manuscripts of randomised trials, as well as to provide feedback to authors on the inconsistencies found, improves the completeness of reporting of published trials.


Options:
A: Arm Label: Intervention arm; Type: EXPERIMENTAL; Interventions: Behavioral: Evaluation of reporting inconsistencies | Arm Label: Control arm; Type: OTHER; Interventions: Behavioral: Standard Peer Review. | Intervention Type: BEHAVIORAL; Name: Evaluation of reporting inconsistencies; Assigned to Arm(s): Intervention arm | Intervention Type: BEHAVIORAL; Name: Standard Peer Review.; Assigned to Arm(s): Control arm
B: Arm Label: SPIRIT checklist plus usual practice; Type: EXPERIMENTAL; Interventions: Other: SPIRIT checklist plus usual practice | Arm Label: Usual practice; Type: OTHER; Interventions: Other: Usual practice | Intervention Type: OTHER; Name: SPIRIT checklist plus usual practice; Assigned to Arm(s): SPIRIT checklist plus usual practice | Intervention Type: OTHER; Name: Usual practice; Assigned to Arm(s): Usual practice
C: Arm Label: C-short plus usual practice; Type: EXPERIMENTAL; Interventions: Other: C-short plus usual practice | Arm Label: Usual practice; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: C-short plus usual practice; Assigned to Arm(s): C-short plus usual practice
D: Arm Label: USUAL PEER REVIEWER; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: COBPeer; Type: EXPERIMENTAL; Interventions: Other: COBPEER | Arm Label: GOLD STANDARD; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: COBPEER; Assigned to Arm(s): COBPeer

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Immunological and Genomic Effects of an Online Mindfulness Program for Stress Management
Brief Summary: This is a prospective parallel non-blinded randomized study with two arms, an intervention group and an active control group.

Sixty healthy, but stressed nurses will be randomly assigned to either participate in a 6-week internet-based mindfulness meditation program produced by the Cleveland Clinic called Stress Free Now for Healers or to listen to relaxing music for at least 5 minutes a day for 6 weeks, and pre-post comparisons will be made for RNA expression profiles, plasma cytokine concentrations, telomerase activity, 6-point salivary cortisol and several self-reported assessments of physical and mental health.


Options:
A: Arm Label: Mindful Awareness Practices (MAPs); Type: EXPERIMENTAL; Interventions: Behavioral: Mindful Awareness Practices (MAPs) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mindful Awareness Practices (MAPs); Assigned to Arm(s): Mindful Awareness Practices (MAPs)
B: Arm Label: Intervention Group; Type: OTHER; Interventions: Behavioral: Internet-Based Mindfulness Program - Stress Free Now for Healers | Arm Label: Active Control Group; Type: OTHER; Interventions: Behavioral: Active Control Group - Relaxing Music | Intervention Type: BEHAVIORAL; Name: Internet-Based Mindfulness Program - Stress Free Now for Healers; Assigned to Arm(s): Intervention Group | Intervention Type: BEHAVIORAL; Name: Active Control Group - Relaxing Music; Assigned to Arm(s): Active Control Group
C: Arm Label: Mental Training for Surgeons; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness Based Stress Reduction - modified | Arm Label: The Mind of a Surgeon; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Active listening and reading | Intervention Type: BEHAVIORAL; Name: Mindfulness Based Stress Reduction - modified; Assigned to Arm(s): Mental Training for Surgeons | Intervention Type: BEHAVIORAL; Name: Active listening and reading; Assigned to Arm(s): The Mind of a Surgeon
D: Arm Label: Electronic intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Electronic intervention suggesting behavioral activity | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Electronic intervention suggesting behavioral activity; Assigned to Arm(s): Electronic intervention

Answer: B